Research To Practice | Oncology Videos

Featuring a slide presentation and related discussion from Dr Gilles Salles, including the following topics: Recent data with polatuzumab vedotin/bendamustine/rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) (0:00) Available data from trials evaluating tafasitamab/lenalidomide, loncastuximab tesirine and selinexor for DLBCL (12:57) Current and future roles of chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies and combination therapies for DLBCL (21:43) CME information and select publications

Featuring an interview with Dr Gilles Salles, including the following topics: Biology underlying B-cell lymphomas, role of Bruton tyrosine kinase (BTK) inhibitors in lymphomas and reason for cure in diffuse large B-cell lymphoma (DLBCL) versus indolent lymphomas (0:00) Efficacy, tolerability and optimal sequencing of selinexor, polatuzumab vedotin/bendamustine/rituximab, tafasitamab/lenalidomide and loncastuximab tesirine for DLBCL (6:32) Ongoing trials evaluating selinexor, tafasitamab/lenalidomide and loncastuximab tesirine for DLBCL (14:24) Managing cytokine release syndrome associated with bispecific antibodies; eligibility considerations with bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy (18:02) Case: A man in his late 60s diagnosed with DLBCL who has a history of ulcerative colitis and mitral valve repair (28:17) Case: A woman in her early 80s with transformed DLBCL (35:14) Case: A woman in her early 40s with DLBCL unresponsive to CAR T-cell therapy (38:05) CME information and select publications

Featuring perspectives from Dr Richard Stone, including the following topics: Current and future trends in the care of patients with acute myeloid leukemia (AML) (0:00) Management of AML with IDH1/2 and FLT3 mutations (17:28) Advances in the treatment of high-risk AML (29:42) Emerging data with novel therapies for AML with targetable mutations (36:53) Hematopoietic stem cell transplantation as a treatment option for patients with relapsed or refractory AML (51:15) Advances in the care of patients with myelodysplastic syndromes (56:19) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma — Faculty Presentation 2: Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Other Novel Approaches for MM — Dr Ajay Nooka CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma — Faculty Presentation 1: Optimizing the Current Management of Multiple Myeloma (MM) — Dr Joseph Mikhael CME information and select publications

Featuring perspectives from Drs Joseph Mikhael and Ajay Nooka, including the following topics: Introduction (0:00) Front-Line Treatment; Autologous Stem Cell Transplant (11:36) Use of Anti-CD38 Antibodies (29:36) CAR T-Cell Therapy (38:16) Treatment with Bispecific Antibodies (48:59) Other Treatments for Relapsed/Refractory Disease (56:07) CME information and select publications

Featuring perspectives from Drs Erica Mayer and Ruth O'Regan, including the following topics: Pregnancy during adjuvant endocrine therapy; fertility issues (0:00) Genomic biomarkers in the adjuvant setting (16:28) CDK4/6 inhibitors in metastatic disease (31:58) Adjuvant use of CDK4/6 inhibitors (47:42) Novel agents in metastatic disease (1:14:26) CME information and select publications

Featuring a slide presentation and related discussion from Professor Giuseppe Curigliano, including the following topics: Recent data with targeted therapies for patients with HER2-positive metastatic breast cancer (0:00) Case: A woman in her early 40s with a new right breast tumor 10 years after adjuvant radiation and endocrine therapy (17:17) Case: A woman in her mid 20s with a family history of breast cancer presenting with a lump in her left breast (26:34) CME information and select publications

Featuring an interview with Professor Giuseppe Curigliano, including the following topics: Vision for treating and curing HER2-positive metastatic breast cancer (mBC) in the future (0:00) Optimal treatment of HER2-positive mBC with brain metastases (7:42) Screening for and management of T-DXd-related interstitial lung disease (17:32) Gastric toxicities associated with the tucatinib/trastuzumab/capecitabine regimen and with T-DXd; differences in the toxicity profiles of these therapies between patients with HER2-positive and HER2-low breast cancer (23:50) Approach to endocrine therapy for triple-positive disease; emerging data with the AKT inhibitor capivasertib (28:43) Case: A woman in her mid 40s with a family history of breast cancer and upper limb soft tissue sarcoma who presents with a right breast lump and axillary adenopathy on self-examination (35:44) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer — Faculty Presentation 2: Therapeutic Approaches for Patients with Other Actionable Genomic Alterations — Dr Gregory Riely CME information and select publications